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Abstract
A radioiodinated derivative of the tumor-homing F3 peptide, (N-(2-{3-[
125I]Iodobenzoyl}aminoethyl)maleimide-F3Cys
peptide, [
125I]IBMF3 was developed for investigation as a SPECT tumor imaging radioligand. For this purpose, we custom
synthesized a modified F3 peptide analog (F3Cys) incorporating a C-terminal cysteine residue for site-specific attachment of
a radioiodinated maleimide conjugating group. Initial proof-of-concept Fluorescence studies conducted with AlexaFluor
532 C5 maleimide-labeled F3Cys showed distinct membrane and nuclear localization of F3Cys in MDA-MB-435 cells.
Additionally, F3Cys conjugated with NIR fluorochrome AlexaFluor 647 C2 maleimide demonstrated high tumor specific
uptake in melanoma cancer MDA-MB-435 and lung cancer A549 xenografts in nude mice whereas a similarly labeled control
peptide did not show any tumor uptake. These results were also confirmed by ex vivo tissue analysis. No-carrier-added
[
125I]IBMF3 was synthesized by a radioiododestannylation approach in 73% overall radiochemical yield. In vitro cell uptake
studies conducted with [
125I]IBMF3 displayed a 5-fold increase in its cell uptake at 4 h when compared to controls. SPECT
imaging studies with [
125I]IBMF3 in tumor bearing nude mice showed clear visualization of MDA-MB-435 xenografts on
systemic administration. These studies demonstrate a potential utility of F3 peptide-based radioligands for tumor imaging
with PET or SPECT techniques.
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Introduction
Recent advances in cellular and molecular biology have made
much progress in unraveling the molecular footprints of
tumorigenesis by identifying abnormalities in signal transduction
pathways and gene alterations associated with cancer initiation
and progression. Although a number of tumor biomarkers have
been identified and their roles construed, the true impact of these
advances is still not apparent in the clinic. This is partly due to the
fact that clinical diagnosis and outcome of therapy is still
determined by assessment of gross structural measurements
obtained several months after therapy administration. Inability
to dynamically monitor biomarker activity within the tumor and
its microenvironment is a major impediment to the improvement
of overall patient survival rates. PET and SPECT imaging
modalities have been proven to be clinically relevant in the
diagnosis and monitoring of therapeutic response of many cancers
[1,2]. Accordingly, there is a an urgent need for improved tumor-
specific PET and SPECT radioligands that home to cancerous
tissue and allow detection and diagnosis of cancer.
F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAK-
K), a 31 amino acid fragment of HMGN2 protein identified by
Ruoslahti’s group using in vivo phage display techniques, has been
shown to bind to tumor and endothelial cells in tumor blood vessels
[3]. Subsequent studies showed that F3 peptide binds to nucleolin at
cell surface and is transported to nucleus in a nucleolin-dependent
manner [4]. Nucleolin is a highly conserved nuclear protein that is
involved in ribosome maturation [5,6]. It also acts as a shuttle
protein that transports cargo between cytoplasm and nucleus [7,8].
In normal cells, nucleolin resides in the nucleus, however in tumor
cells it is reported to shuttle between the cell surface and nucleus
[9,10]. Because of its distinct localization on tumor cell membrane,
specific antagonists of cell surface nucleolin are being actively
investigated for tumor targeting [4,11].
We have previously shown that F3 peptide aids in targeting and
retention of multifunctional nanoparticles to tumor and its milieu
[12,13].The tumor-homing and internalizing properties of F3
peptide make it an attractive candidate as a scaffold for develop-
ment of novel radioligands for PET or SPECT tumor imaging.
Herein, we report the development of an [
125I]-labeled F3 peptide
conjugate as a SPECT tumor imaging radioligand and its initial
proof-of concept preclinical mouse imaging studies.
Results and Discussion
Synthesis of Fluorescent-tagged F3Cys peptide
Common methods for peptide labeling utilize the conjugation of
prosthetic groups such as succinimidyl esters to the e-amino group
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peptide by this approach is problematic since it contains a total of
9 lysine residues. Consequently, our strategy for site-specific
functionalization focused on labeling at the free thiol of a suitable
cysteine-modified F3 peptide analog. Thiol-specific reagents
such as maleimides have been shown to display high chemoselec-
tivity as compared to amino or carboxylate-reactive reagents [15,
16]. Accordingly, we custom synthesized a modified F3 peptide
analog incorporating a cysteine residue at the C-terminus (F3Cys)
for site specific coupling to a radioiodinated maleimide conjugat-
ing group. We chose a meta-[
125I]iodobenzamide group tethered to
a maleimide as our labeled conjugating moiety since meta-
substituted aromatic radioiodine labels are known to demonstrate
high stability towards in vivo metabolic deiodination [17,18].
AlexaFluor 532 C5 maleimide-labeled F3Cys (AF532-F3Cys (1a),
Figure 1A) was synthesized to investigate the sub-cellular distribu-
tion of F3Cys. We also labeled F3Cys with the Near Infrared
(NIR) fluorochrome AlexaFluor 647 C2 maleimide (AF647-F3Cys
(1b); Figure 1A) for in vivo optical imaging studies. To demonstrate
that the tumor localization of F3Cys conjugate was specific to the
F3 peptide sequence, the corresponding AlexaFluor 647 C2
maleimide conjugate of a control peptide (AF647-Control (2),
Figure 1B) incorporating cysteine at the C-terminus was also
synthesized.
In vitro Cell Studies with AlexaFluor 532 C5 maleimide-
labeled F3Cys (AF532-F3Cys)
When MDA-MB-435 cells were grown in media containing
10% serum and stained with AF532-F3Cys, cell surface and
nuclear staining of F3Cys was observed. On the other hand, serum
starved cells showed predominantly nuclear staining without
significant membrane staining suggesting that F3Cys localizes to
cell surface in actively growing cells (Figure 2A). This pattern of
staining has been previously demonstrated for F3 peptide and
corresponds to the subcellular distribution of nucleolin in serum-
starved as well as proliferating cells [3].
In Vivo Studies with Fluorescent-labeled F3Cys and
Control peptides
Nude mice with MDA-MB-435 xenografts were injected i.v.
with AF647-F3Cys or AF647-Control peptide and imaged using
an in vivo fluorescence imaging system. Tumor specific uptake at
2 h was observed only with AF647-F3Cys but not with AF647-
Control peptide (Figure 2B). Tumor retention of AF647-F3Cys
was also observed at 24 h post injection albeit at lower levels (data
not shown). In addition to tumor, there are other sites which show
fluorescence signal in the images. We believe that this likely
represent kidney uptake (see below). Further, to validate that F3
imaging of tumor is also applicable to other tumor models, we
imaged A549 lung tumor xenografts in nude mice. Similar to the
MDA-MB-435 in vivo imaging studies, the A549 tumor also
selectively retained AF647-F3Cys, while the AF647-Control
peptide did not display any tumor localization (Figure 2C). These
studies confirm that F3Cys retains the tumor-localizing properties
of F3 peptide. Additionally, parallel imaging studies with the
labeled control peptide confirm that the tumor localization of the
AF647-F3Cys was specific to the F3 peptide sequence.
To validate the fluorescence imaging data, animals were
sacrificed and tumors and excretory organs were harvested for ex
vivo fluorescence analysis. In addition to tumors, a high
fluorescence signal was observed in kidney and liver (Figure 2D).
Kidney and liver uptake was also seen with animals injected with
Figure 1. Fluorescent- and [
125I]-labeled F3Cys Analogs. Structures of fluorescent and radioiodinated F3Cys and control peptide analogs
investigated in this study (for details see text).
doi:10.1371/journal.pone.0022418.g001
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observed. This suggests that non-tumor signal observed in whole
body imaging likely represents kidney and liver uptake.
Synthesis of radioiodinated F3Cys peptide ([
125I]IBMF3)
The structure of the target radioligand ([
125I]IBMF3) chosen for
synthesis and investigation is shown in Scheme B (Figure 3). Prior
to radioligand synthesis, the non-radioactive analog (IBMF3, 6)
was synthesized for method optimization and structure character-
ization by the approach shown in Scheme A (Figure 3). Initially,
conversion of 3-iodobenzoic acid (3) to the corresponding
succinimidyl ester 4 was achieved in 97% yield using di-(N-
succinimidyl)carbonate in pyridine/CH3CN. Treatment of 4 with
N-(2-aminoethyl)maleimide and DIPEA at moderately elevated
temperatures provided the non-radioactive iodinated maleimide
conjugate reagent 5 in 58% yield. Conjugation of 5 to F3Cys
peptide and subsequent HPLC purification of the non-radioactive
iodinated peptide conjugate 6 was conducted as described for the
synthesis of the fluorescence-tagged ligands.
Synthesis of radioiodinated F3Cys peptide ([
125I]IBMF3) was
conducted using a radioiododestannylation approach (Scheme B).
The 3-(tri-n-butylstannyl)maleimide analog 8 was obtained from
the N-succinimidyl-3-(tri-n-butylstannyl)benzoate analog 7 using
the approach described for the synthesis of 5 (Scheme A).
Radioiododestannylation of intermediate 8 with Na
125I using
NCS as oxidizing agent provided [
125I]5 in 89% radiochemical
yield and .99% radiochemical and chemical purity after HPLC
purification. The radioiodinated product was well resolved from
the tri-n-butylstannyl starting material (Rt.25 min) under the
HPLC conditions. Conjugation of [
125I]5 to F3Cys peptide was
carried out in a mixture of DMSO and PBS buffer at 4uC.
Radioiodinated F3Cys peptide conjugate [
125I]IBMF3 was
Figure 2. In vitro and in vivo optical imaging using Fluorescent-labeled F3Cys peptides. MDA-MB-435 cells, in optically clear bottom dishes,
cultured in either serum free or serum containing media were stained with AF532-F3Cys, counterstained with DAPI and monitored under a
fluorescent microscope (A). Mice bearing MDA-MB-435 (B) or A549 (C) xenografts were injected i.v. via the tail vein with either AF647-F3Cys (1b)o r
AF647-Control peptide (2). Fluorescence images were acquired over time and a representative image obtained at 2 h is shown (B and C). Ex vivo
fluorescence imaging of tumor, kidney and liver harvested 2 h after AF647-F3Cys peptide injection in animals bearing A549 tumor xenograft (D).
doi:10.1371/journal.pone.0022418.g002
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radiochemical and chemical purity after HPLC purification
(Method II). Under these HPLC conditions, [
125I]IBMF3 was
well separated from F3Cys peptide (Rt=16.1 min). The average
specific activity of [
125I]IBMF3 was determined to be 17936164
Ci/mmol (N=3). The radioligand which was formulated in
PBS:EtOH [95:5] was stable for at least 1 week when stored at
5uC( ,2% radiolytic decomposition by radio-HPLC analysis).
In Vitro Cell Uptake Studies with [
125I]IBMF3
The cellular uptake of [
125I]IBMF3 was determined by
incubating MDA-MB-435 cells with [
125I]IBMF3 for 4 h in
presence or absence of F3Cys. An almost 5-fold increase in
[
125I]IBMF3 uptake was observed at 4 h when compared to
controls (Figure 4A). Further, competition with unlabeled F3Cys
peptide reduced the uptake of [
125I]IBMF3 to levels seen in
controls, confirming the specificity of its cell uptake.
Figure 3. Synthesis of [
125I]IBMF3. Chemical synthetic approach for preparation of non-radioactive IBMF3 (6)( Scheme A) and [
125I]IBMF3
(Scheme B) (See text for details).
doi:10.1371/journal.pone.0022418.g003
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SPECT imaging studies conducted following i.v. administration
of [
125I]IBMF3 to nude mice bearing MDA-MB-435 tumor
xenografts showed distinct uptake of radioactivity in tumor as early
as 15 min post-injection (Figure 4B). Non-target accumulation of
radioactivity was mainly in kidney and bladder between 15 min
(Figure 4B) and 2 h (data not shown) suggesting that renal
elimination was the major excretory pathway. At 4 h, kidney and
bladder were not visualized likely due to voiding of urine. It is
possible that the presence of urine radioactivity in kidney and
bladder, at the early time intervals, could have contributed to an
overestimation of tissue radioactivity uptake in these organs in the
images. Tumors were also visualized in the SPECT images at 4 h
although at lower levels compared to the 15 min and 2 h images.
Tumor uptake of radioactivity displayed substantial clearance at
later time intervals (.4 h) resulting in poor image visualization of
tumor. Intestinal radioactivity was clearly apparent in the 4 h
images, which is most likely due to a shift in radioactivity clearance
from the renal to hepatobiliary excretion pathway at later time
intervals. Moderate radioactivity uptake was seen in thyroid
indicating that [
125I]IBMF3 is relatively stable towards in vivo
deiodination.
Biodistribution Studies
The uptake of radioactivity in selected tissues was determined
following intravenous administration of [
125I]IBMF3 to MDA-
MB-435 tumor-bearing athymic nude mice. Mice were injected
intravenously with 7.8–10 mCi of [
125I]IBMF3 and sacrificed at
designated time intervals (5 min, 30 min, 1 h, and 4 h post-
injection). These results are summarized in Figure 5 and complete
biodistribution results are presented in Supplementary data (Table
S1). [
125I]IBMF3 displayed high radioactivity accumulation in
kidney and to a lesser extent in liver at the early time intervals.
Kidney uptake of radioactivity (5.68%ID/g and 10.8% ID/g at 5
and 30 min respectively post-injection) was the highest among all
sampled tissues confirming that renal elimination is the major
excretory pathway for the radioligand (Table S1). In tumors,
radioactivity levels peaked at 30 min post-injection (1.05% ID/g).
Although initial blood levels of radioactivity were moderately high
(0.84% ID/g at 30 min) this tissue displayed a .60% radioactivity
clearance between 30 and 60 min resulting in tumor-to-muscle
and tumor-to-blood ratios of 4.3 and 2.1, respectively, at 60 min
post-injection (Figure 5B and 5C). Moderate radioactivity uptake
was seen in thyroid (maximal uptake of 4% ID/g at 4 h) indicating
that the radioligand is relatively stable towards in vivo deiodination
(Supplementary data). As expected due to its highly hydrophilic
nature, [
125I]IBMF3 displayed very low extraction into brain
(0.03%ID/g at 5 min post-injection; data not shown). No
appreciable radioactivity uptake was seen in other sampled tissues
such as spleen, adrenal and heart.
Radioligand Metabolism
The metabolic stability of [
125I]IBMF3 in blood and urine was
investigated at 5 min post-injection in tumor-bearing athymic
nude mice by HPLC analysis of the relative amounts of parent
radioligand and radiometabolites. Analysis of plasma samples
showed that 24.6% of the total radioactivity at 5 min post-
injection was associated with intact [
125I]IBMF3. The remaining
radioactivity consisted primarily of two hydrophobic radiometa-
bolites representing 47% and 18% of the total plasma radioac-
tivity. Free radioiodide (
125I) accounted for 6.4% of the plasma
radioactivity. In contrast, the parent radioligand accounted for
42% of the total radioactivity present in mouse urine samples at
this time interval. The remaining radioactivity consisted of three
major hydrophobic radiometabolites representing 28%, 6.8% and
10% of the total. Thus, despite its limited availability in blood as
the intact radioligand at early time points, [
125I]IBMF3 still
provided clear visualization of tumors in the SPECT images up to
Figure 4. In vitro cell uptake and in vivo SPECT imaging with [
125I]IBMF3. (A) MDA-MB-435 cells were incubated with [
125I]IBMF3 either alone
or in the presence of F3Cys for 0 h or 4 h and uptake of [
125I]IBMF3 was measured. To determine non-specific binding cells in control group were
treated with [
125I]IBMF3, the media removed immediately after addition of the radioligand and processed as for the experimental group. All
experiments were performed in triplicate and repeated at least thrice. The data presented here is an average of radioactivity counts per well +/2 SD.
(B) Mice bearing MDA-MB-435 xenografts were injected i.v. via the tail vein with [
125I]IBMF3 and animals were serially imaged post injection.
Representative images obtained at 15 min and 4 h post-injection are shown.
doi:10.1371/journal.pone.0022418.g004
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affinity which results in its rapid sequestration and retention within
the tumor cells in a nucleolin dependent manner.
Conclusion
Our studies show a potential utility of the tumor-homing F3
peptide as a radiodiagnostic for PET or SPECT tumor imaging.
Tumor homing peptides have several advantages over antibodies
or large proteins due to minimal non-specific uptake by the reticu-
loendothelial system and the low likelihood of an immune response
because of their smaller size. Additionally, PET and SPECT
imaging approaches offer unique advantages including, high
sensitivity, as well as, tomographic, deep tissue and repetitive
imaging capabilities. Further, these imaging techniques are
directly translatable to clinical application. In previously reported
preclinical studies, F3 peptide has been utilized to target a payload
to tumor sites. These include theranostic nanoparticles (reported
by our laboratory [12,13]), magnetic nanoworms [19], quantum
dots harboring siRNA [20], hydrogel-based nanoparticles harbor-
ing therapeutic agents [21–23], fluorescent probes [3,12] and
transduction baculovirus to tumors [24]. Additionally, Drecoll et al
recently demonstrated the use of F3 peptide conjugated with
213Bi
or
68Ga for application for tumor radiotherapy and PET imaging,
respectively, in a mouse model of peritoneal carcinomatosis [25].
In their reported tissue biodistribution studies, i.p.-administered
[
213Bi]-labeled F3 peptide displayed superior tumor uptake and
tumor-to-blood and tumor-to-muscle ratios in their tumor model
in comparison to our results with i.v. administered [
125I]IBMF3 in
the MDA-MB-435 tumor xenograft mouse model. The enhanced
tumor uptake of radioactivity seen in these studies could be due to
high local radiotracer availability in the tumor vicinity as a
consequence of intraperitoneal administration.
The high renal clearance of [
125I]IBMF3 and its subsequent
moderate levels of tumor uptake following systemic administration,
could pose a challenge to SPECT imaging of deep tissues in close
proximity to these organs. High renal excretion of radioactivity
was also seen by Drecoll et al [25] in their studies with [
213Bi]-
conjugated F3 peptide. It is possible that a structurally modified
version of this radioligand may offer more suitable in vivo
pharmacokinetics including reduced renal clearance and conse-
quently higher tumor uptake for SPECT imaging. One potential
approach to retard renal clearance would be to incorporate a more
hydrophobic linker for radiolabel attachment to F3Cys peptide.
Alternatively, modifications such as the use of D amino acids,
glycosylation or the masking of C or N termini could also be
utilized for improvement of its pharmacokinetic properties as
previously reported for RGD or other peptides [26–28]. Studies in
this regard are currently underway in our laboratory.
Materials and Methods
Chemicals and Radiochemicals
Cysteine-modified F3 peptide (KDEPQRRSARLSAKPAPPK-
PEPKPKKAPAKKC; F3Cys) was custom synthesized by Poly-
Peptide Laboratories, Torrance, CA using standard solid-phase
fluorenylmethoxycarbonyl (Fmoc) chemistry techniques. Control
peptide (AAVALLPAVLLALLAPESASGASADASVNFLC) was
synthesized by Peptide 2.0 Corp., Chantilly, VA, and Alexa Fluor
647 C2 maleimide was obtained from Invitrogen Corp., Carlsbad,
CA. All other chemical reagents were obtained from Aldrich
Chemical Co., Milwaukee, WI. Sodium [
125I]iodide was obtained
from MDS Nordion Inc. (Ottawa, Canada) as a no-carrier-added
solution in aqueous 0.01 N NaOH (pH 10–12).
Instrumentation and Analyses
Melting points were determined with a Thomas-Hoover melting
point apparatus and are uncorrected. Thin-layer chromatography
(TLC) was performed using Analtech silica gel GF Uniplates
(250 micron). TLC plates were visualized after development with
either ultraviolet (UV) light or by spraying with phosphomolybdic
acid reagent with subsequent heating.
1H NMR spectra were
recorded on a Varian INOVA instrument operating at 400 MHz
using CDCl3, or DMSO-d6 as solvent and tetramethylsilane
(TMS) as internal standard. Chemical shifts (d) and coupling
constants (J) are reported in parts per million (ppm) and Hertz
(Hz), respectively. Compound elemental analysis data were
obtained at the Department of Chemistry, University of Michigan.
High resolution mass spectral analyses were performed at the
Department of Chemistry, University of Michigan, using either a
VG-70-250-S mass spectrometer for electron impact (EI) and
Figure 5. Tissue biodistribution of [
125I]IBMF3 in MDA MB-435 tumor bearing mice. Mice (n=4 per time interval) were injected via tail vein
with [
125I]IBMF3 and tissues were harvested for radioactivity uptake. (A) Tissue distribution at 60 min post injection and reported as percent injected
dose per gram of tissue (%ID/g). (B) and (C) represent the ratio of radioactivity in tumor to blood and tumor to muscle respectively at various time
intervals. All the data are computed as mean +/2 SEM.
doi:10.1371/journal.pone.0022418.g005
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instrument with an electrospray interface for electrospray
ionization (ESI) mode or a Waters Tofspec-2E run in reflectron
mode. Elemental analyses were conducted by Atlantic Microlab
Inc., Norcross, GA. HPLC was performed using a Waters Breeze
HPLC System (Waters Corporation, Milford, MA) equipped with
a Waters 2487 Dual Wavelength Absorbance Detector. Radioac-
tivity was monitored with a Bioscan Flow Count FC-3300 NaI/
PMT Radiodetector (Bioscan, Inc., Washington, DC) equipped
with a 1.5061.50 NaI(Tl) crystal. HPLC analysis and purification
were conducted at ambient temperature on a Waters Sunfire C-18
column (4.66250 mm), 5 m particle, with 0.1% TFA in H2O (A)
and 0.1% TFA in CH3CN (B) solvent mixtures with UV
absorbance (215 and 254 nm) and radioactivity detection. HPLC
runs were conducted using either of the following methods:
Method I [Initial gradient elution from 90% A to 5% A over
25 min; flow rate of 1 mL/min]; Method II [Initial gradient
elution from 92% A to 84% A over 32 min followed by 84% A to
68% A over 8 min; flow rate of 1.5 mL/min]. Radioactivity
measurements were obtained with a Capintec CRC-15W
Radioisotope Dose Calibrator (Ramsey, NJ) and specific activity
estimates were determined from a standard curve relating mass to
UV absorbance peak area.
General Method for Synthesis of Alexa Fluor Maleimide-
labeled Peptide Conjugates (1a, 1b and 2)
The method of preparation of compound 1b is described as an
example. A solution of Alexa Fluor 647 C2 maleimide reagent
(1 mg, 0.77 mmol) in DMSO (150 ml) was added to a stirred
solution of F3Cys peptide (0.77 mmol) in 150 mL of DMSO. The
mixture was stirred in the dark under a nitrogen atmosphere at
ambient temperature for 18 h, at which point, HPLC analysis
(Method II) showed completion of reaction. HPLC purification
afforded the fluorescence-tagged peptides in 69–83% yields. Rt
(1a)=34.3 min; Rt (1b)=35.5 min; Rt (2)=26.1 min.
N-Succinimidyl-3-iodobenzoate (4)
The title compound was synthesized in 97% yield from 3-
iodobenzoic acid (3) using a general method described by
Koziorowski et al [29]; mp 147–148uC.
1H NMR (DMSO-d6): d
8.36 (t, 1H, J=1.6 Hz), 8.23 – 8.21 (m, 1H), 8.13 – 8.10 (m, 1H),
7.47 (t, 1H, J=7.9 Hz), 2.91 (s, 4H). HRMS [EI, 70 eV]: Calcd
for C11H8NO4I: 344.9498 [M
+]. Found: 344.9492. Anal.
(C11H8NO4I): C, H, N.
N-(2-{3-Iodobenzoyl}aminoethyl)maleimide (5)
A solution of 4 (51 mg, 0.1 mmol) in anhydrous DMSO
(0.6 mL) was treated sequentially with N-(2-aminoethyl)maleimide
trifluoroacetate salt (26 mg, 0.1 mmol) and (i-Pr)2NEt (0.02 mL,
0.11 mmol) and stirred at 50–55uC for 3 h under an argon
atmosphere. Brine was added to the reaction, the mixture was
extracted with EtOAc and the combined organic layers were
washed with brine, H2O, and dried (Na2SO4). The crude product
was purified by flash chromatography on silica gel (20–40%
EtOAc in hexanes) to give the title compound in 58% yield as a
white crystalline solid: mp 171–172uC;
1H NMR (DMSO-d6): d
8.65 (t, 1H, J=5.9 Hz), 8.07 (t, 1H, J=1.7 Hz), 7.89 – 7.86 (m,
1H), 7.75 – 7.72 (m, 1H), 7.26 (t, 1H, J=7.8 Hz), 7.02 (s, 2H),
3.57 (t, 2H, J=5.6 Hz), 3.41 – 3.37 (m, 2H). HPLC (Method I;
Rt=15.7 min) HRMS [ESI with Na
+ added]: Calcd for
C13H11N2O3INa: 392.9712 [M+Na
+]. Found: 392.9707. Anal.
(C13H11N2O3I): C, H, N.
Synthesis of Iodinated F3-Cys Peptide Conjugate (6,
IBMF3)
The title compound was prepared as described above by
addition of a solution of 5 (0.9 mg, 2.2 mmol) in DMSO (50 ml) to
a stirred solution of F3-Cys peptide (7 mg, 1.98 mmol) in PBS
buffer (100 mL, pH 7.0). The product was purified by HPLC
(Method II; Rt=35.4 min) to afford 6 in 76% yield. HRMS
{MALDI TOF}: Calcd for C168H279N52O45IS: 3906. Found:
3907 [MH+].
N-Succinimidyl-3-(tri-n-butylstannyl)benzoate (7)
The title compound was obtained in 63% yield as a colorless oil
from compound 4 using the general approach of Dekker and
coworkers [30].
1H NMR (CDCl3): d 8.19 (s, 1H), 8.07 – 8.04 (m,
1H), 7.77 – 7.75 (m, 1H), 7.44 (t, 1H, J=7.5 Hz), 2.91 (s, 4H),
1.57 – 1.50 (m, 6H), 1.37 – 1.28 (m, 6H), 1.12 – 1.08 (m, 6H), 0.93
– 0.87 (m, 9H). HRMS [ESI with Na
+ added]: Calcd for
C23H35NO4Sn: 532.1486 [M+Na
+]. Found: 532.1509.
N-(2-{3-(tri-n-Butylstannyl)benzoyl}aminoethyl)maleimide
(8)
A solution of 7 (51 mg, 0.1 mmol) in anhydrous DMSO
(0.6 mL) was treated sequentially with N-(2-aminoethyl)maleimide
trifluoroacetate salt (26 mg, 0.1 mmol) and (i-Pr)2NEt (0.02 mL,
0.11 mmol) and stirred at 50–55uC for 3 h under argon. Brine was
added to the reaction, the mixture was extracted with EtOAc and
the combined organic layers were washed with brine, H2O, and
dried (Na2SO4). The crude product was purified by flash
chromatography on silica gel (20–40% EtOAc in hexanes) to give
the title compound in 53% yield as an off-white amorphous solid.
1H NMR (CDCl3): d 7.86 - 7.85 (m, 1H), 7.72 – 7.63 (m, 1H), 7.59
– 7.52 (m, 1H), 7.39 – 7.35 (m, 1H), 6.73 (s, 2H), 6.66 (br t, 1H),
3.86 - 3.83 (m, 2H), 3.69 – 3.65 (m, 2H), 1.57 – 1.50 (m, 6H), 1.37
– 1.28 (m, 6H), 1.11 – 1.02 (m, 6H), 0.94 – 0.85 (m, 9H).
(Rt=34.12 min; 90:10 to 5:95) HRMS [ESI with Na
+ added]:
Calcd for C25H38N2O3SnNa: 557.1802 [M+Na
+]. Found:
557.1796. Anal. (C25H38N2O3Sn): C, H, N.
Synthesis of [
125I]-labeled F3-Cys Peptide Conjugate
([
125I]IBMF3)
A solution of 4.6 mCi of Na
125I in 0.01 N NaOH in a 2 mL
glass vial was partially neutralized with an equal volume of 3 mM
H3PO4 solution. A solution of the stannyl maleimide compound 8
(40 mg) in CH3OH (40 mL) and 10% HOAc in CH3OH (40 mL)
were then added sequentially to the vial followed by immediate
addition of a solution of N-chlorosuccinimide (20 mg) in CH3OH
(20 mL). The reaction was quenched after 5 min with aq. Na2S2O5
solution (20 mL; 20 mg) and purified by HPLC (Method I; Rt of
[
125I]5=15.8 min) to give 4.1 mCi (89% radiochemical yield) of
[
125I]5 with .99% radiochemical purity.
A solution of 3.9 mCi of [
125I]5 in DMSO (100 mL) was treated
with a solution of 1 mg (0.3 mmoles) of F3Cys peptide in 600 mLo f
PBS buffer (pH 7.0) and the reaction mixture was stored overnight
at 4uC. The crude product was purified by HPLC (Method II; Rt
of [
125I]IBMF3=35.7 min) and the product fraction was col-
lected, diluted with H2O (10 mL) and eluted through a Waters C-
18 Sep Pak cartridge (pre-conditioned by sequential elution with
10 mL each of 0.1% TFA in CH3CN [Eluant A] and 0.1% TFA
in H2O [Eluant B] mixtures). The Sep Pak was eluted with Eluant
A (10 mL) and [
125I]IBMF3 was subsequently rinsed off the
cartridge with 2 mL of Eluant B. The product solution was
concentrated to dryness using a nitrogen stream and formulated in
PBS:EtOH [95:5] to afford 3.2 mCi of [
125I]IBMF3 (Overall Rad.
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17936164 Ci/mmol (N=3).
Cell Culture
A549 (human lung cancer cell line), purchased from American
Type Culture Collection (ATCC, Manassas VA) and MDA-MB-
435 (human melanoma) cells [31] were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum, 1% sodium pyruvate and 1% nonessential amino acids at
37uC in a humidified atmosphere containing 5% carbon dioxide.
Tumor cells were harvested when they reached near confluence by
incubation with 0.05% trypsin-EDTA. Cells were pelleted by
centrifugation at 4506 g for 5 min and re-suspended in sterile
phosphate-buffered saline.
Fluorescence Microscopy studies using AF532-F3Cys
MDA-MB-435 cells were grown in optically clear bottom dishes
(MatTek Corporation, Ashland, MA) and cells were incubated
with serum free or 10% serum harboring DMEM media. Cells
were then fixed with 3.5% paraformaldehyde followed by
treatment with 70% ethanol. AF532-F3Cys (4 mg/2 ml) was
added to cells for 2 h. At the end of the incubation cells were
washed, counterstained with DAPI (1 mg/ml) and observed under
Nikon TE2000U inverted fluorescent microscope. Images were
captured using color camera (Nikon, Melvile NY) and MetaMorph
version 4.6.5 software (Universal Imaging Downingtown, PA).
In Vitro Cell Uptake Studies with [
125I]IBMF3
The uptake of [
125I]IBMF3 was investigated in MDA-MB-435
cells. Cells were seeded in 6-well dishes. For treatment group, cells
were incubated for up to 4 h at 37uC with [
125I]IBMF3 (0.1 mCi
per well) and various concentrations of added cold 6 (none
[0 mM], 0.5 mM and 1.0 mM). For the control group, cells were
similarly treated with [
125I]IBMF3 but the media was removed
immediately after addition of radioligand. Both control and
treated cells were washed twice with ice-cold PBS at the end of
incubation, cells collected by scraping and assayed for radioactivity
using a Gamma Counter.
Animal Models
Animal protocols were approved by the University Committee
on the Use and Care of Animals (UCUCA approval #09583) at
the University of Michigan. Prior to use, MDA-MB-435 cells were
trypsinized, counted and suspended in serum-free DMEM media
for tumor implantation. Six- to eight-week old nu/nu athymic mice
were maintained in ventilated cages and fed/watered ad libitum
and the experiments were carried out under an UCUCA approved
protocol as well as following University of Michigan guidelines for
the humane use of animals in research. Using sterile surgical
scissors, an inverted Y-shaped skin incision over the lower
abdomen was made and the skin was retracted with sterile forceps
to expose the mammary fat pads. MDA-MB-435 tumor cells
(2610
6) were then injected in a total volume of 50 ml using a 22
gauge needle. The surgical incision was closed with Vetbond and
the rate of tumor growth was monitored over a 2–3 week period
using caliper measurements of tumor cross diameters to provide
tumor volumes. For Fluorescence imaging MDA-MB-435 and
A549 xenografts were grown subcutaneously (s.c.) in the lower
flank of the mice. Animals developed tumors after 14–21 days. For
ex vivo analysis, animals were sacrificed 2 h after administration of
peptide and tumor and excretory organs were harvested.
Fluorescence was monitored as described below in in vivo
fluorescence imaging.
In Vivo Fluorescence Imaging
Mice with established subcutaneous MDA-MB-435 tumors in
the flanks were intravenously injected with 50 ul (1 mg/ml
solution in normal saline containing 5% ethanol) of either
AF647-F3Cys or AF647-Control peptide. In vivo fluorescence
imaging was carried out using an IVIS Spectrum (Caliper Life
Science, Hopkinton, MA) imaging system with 640 nm excitation
and 680 nm emission band-pass filters and epi-illumination
excitation light. Animals were imaged at 5 min, 1 h, 4 h and
24 h post-injection.
SPECT/CT Imaging
Mouse SPECT/CT imaging studies were performed on a GMI
Tri-Modality CT/PET/SPECT small animal scanner (Gamma-
Medica Ideas, Inc., Northridge, CA). SPECT images were
acquired using a dual-head, high-resolution, low-energy parallel-
hole collimator. CT imaging of animals was performed for
anatomical co-registration and CT fusion of SPECT images were
performed using AMIRA (version 3.1) software (Visage Imaging,
San Diego, CA USA). Imaging was performed when tumors
reached a 60–100 mm
3 average volume. Animals under isofluor-
ane anesthesia were injected via the tail vein with [
125I]IBMF3
(570–610 mCi in 100 mL of PBS:EtOH [95:5]) and a series of
image acquisitions were obtained at 5 min, 30 min, 1 h, 2 h, 4 h
and 24 h post-injection.
Biodistribution Studies
Female CD-1 nude mice (nu/nu, 25–28 g) bearing MDA-MB-
435 mammary fat pad tumor xenografts on opposite sides were
utilized for the biodistribution studies. Four animals (N=4) were
used per time point. The radioligand (7.8–10 mCi of [
125I]IBMF3
in 100 mL of PBS:EtOH [95:5]) was injected intravenously and
animals were sacrificed by cervical dislocation at designated time
intervals (5 min, 30 min, 1 h and 4 h post-injection). Selected
tissues (blood, heart, liver, lung, spleen, adrenals, tumor, kidney,
muscle, whole brain and thyroid) were harvested and tissue
samples were assayed for activity using a Gamma Counter. Tissue
uptake was computed as % injected dose/gram (%ID/g).
Analysis of Mouse Blood and Urine Metabolites of
[
125I]IBMF3
Female, athymic nude mice (N=2) bearing MDA-MB-435
tumors were injected intravenously with approximately 570–
610 mCi of [
125I]IBMF3 in 100 mL of PBS:EtOH [95:5] and
sacrificed 5 min later. Blood and urine samples were collected,
centrifuged at 12,000 rpm for 15 min, and the supernatants
transferred to a fresh centrifuge tube and the centrifugation
repeated. The supernatants were treated with CH3CN and
centrifuged again to precipitate proteins and the clear supernatants
analyzed by radio-HPLC (Method I). The percentages of
[
125I]IBMF3 and radiometabolites were determined by measuring
the radioactivity of the respective isolated HPLC fractions using a
calibrated Gamma Counter and also by integration of their
respective HPLC peak areas.
Supporting Information
Table S1 Biodistribution of i.v. administered
[
125I]IBMF3 in selected tissues at various time points
post injection. Mice (n=4 per time interval) were injected via
tail vein with [
125I]IBMF3 and tissues were harvested for
radioactivity uptake. Distribution of [
125I]IBMF3 at various time
points post injection was monitored by determining the radioac-
tivity in the different tissues and tabulating them as percent
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